Literature DB >> 2900422

Reversal of hepatic coma with flumazenil with improvement in visual evoked potentials.

D A Burke, K W Mitchell, H al Mardini, C O Record.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2900422     DOI： 10.1016/s0140-6736(88)90146-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  6 in total

Review 1.  Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist.

Authors:  R N Brogden; K L Goa
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

Review 2.  Pathophysiology and clinical basis of prevention and treatment of complications of chronic liver disease.

Authors:  S Wagner; H U Lautz; M J Müller; F W Schmidt
Journal:  Klin Wochenschr       Date:  1991-02-06

3.  Flumazenil does not improve hepatic encephalopathy associated with acute ischemic liver failure in the rabbit.

Authors:  C C van der Rijt; R J de Knegt; S W Schalm; O T Terpstra; K Mechelse
Journal:  Metab Brain Dis       Date:  1990-09       Impact factor: 3.584

4.  Evidence for the presence of a benzodiazepine receptor binding substance in cerebrospinal fluid of a rabbit model of hepatic encephalopathy.

Authors:  K D Mullen; J V Martin; W B Mendelson; K Kaminsky-Russ; E A Jones
Journal:  Metab Brain Dis       Date:  1989-12       Impact factor: 3.584

Review 5.  Flumazenil in the treatment of portal systemic encephalopathy--an overview.

Authors:  K Gyr; R Meier
Journal:  Intensive Care Med       Date:  1991       Impact factor: 17.440

6.  Functional integrity of benzodiazepine receptors of the geniculo-striate visual pathways in Creutzfeldt-Jakob disease. A pharmacological evoked potential study.

Authors:  U Aguglia; R L Oliveri; A Gambardella; A Quattrone
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.